Travere Therapeutics Inc Corporate Analyst Meeting Transcript
Good afternoon, and good morning. Thank you all for joining us today, and welcome to Travere Therapeutics Inaugural Research and Development Day. My name is Chris Cline, and I have the privilege of hosting today's event. We have an insightful program planned. It includes expert perspectives on rare kidney disorders, focal segmental glomerulosclerosis or FSGS, and IgA nephropathy, as well as a comprehensive overview and outlook for our sparsentan programs in these indications. We will also highlight the latest addition to our pipeline, TVT-058, which was previously known as OT-58 and is in Phase I/II development for the treatment of classical HCU.
We are honored today to be joined by guest speakers, Dr. Jonathan Hogan and Dr. Jonathan Barratt. Dr. Hogan is the Assistant Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania, Clinical Director for the Penn Glomerular Center. He will be sharing his perspectives on the current unmet needs and the landscape in FSGS. Dr. Barratt joins
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |